A Randomized Phase 2 Study of Subcutaneous Daratumumab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone Alone in Patients with Multiple Myeloma who have been Previously Treated with Intravenous Daratumumab to Evaluate Retreatment (LYNX)

Category Primary study
JournalCLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Year 2019
This article has no abstract
Epistemonikos ID: f1b49ac3a2eaa78ae6f17655bed5dae94a5172f0
First added on: Feb 11, 2025